The American College of Rheumatology praised the recent announcement from the Centers for Medicare & Medicaid Services (CMS) that their initial drug pricing negotiations have reduced costs for select medications, including significantly lower prices for Enbrel and Stelara, which are frequently used to treat rheumatic diseases.

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.

JAMA Dermatology has published a review of dermatomyositis (DM), focusing on similar and different manifestations of DM.

DM affects all races, but it has been suggested that racial and ethnic minority patients may have more severe disease and a different autoantibody profile. This analysis characterizes the clinical features and outcomes of DM in Hispanic and non-Hispanic patients.

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com - leading with lupus because everyone wants to know about lupus!

An international cohort study of patients with calcium pyrophosphate deposition (CPPD) disease, i.e., recurrent acute CPP crystal arthritis, chronic CPP crystal inflammatory arthritis, and crowned dens syndrome (CDS) identifies both acute and chronic inflammatory phenotypes, each with distinctive clinical and imaging diagnostic features.

JAMA reports that following the COVID-19 pandemic US adults trust in physicians and hospitals decreased, and was associated with lower odds of COVID vaccination.

Lancet Rheumatology has published a review of Calcium pyrophosphate deposition (CPPD) disease - a chronic inflammatory and degenerative crystal arthropathy that increases with aging.